Cargando…
Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
Objective: Vaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, limited data exist for cancer patients under systemic therapy. Methods: In this cohort, we prospectively enrolled cancer patients treated with PARPi as well as healthy volu...
Autores principales: | Liontos, Michalis, Terpos, Evangelos, Markellos, Christos, Zagouri, Flora, Briasoulis, Alexandros, Katsiana, Ioanna, Skafida, Efthymia, Fiste, Oraianthi, Kunadis, Elena, Andrikopoulou, Angeliki, Kaparelou, Maria, Koutsoukos, Konstantinos, Gavriatopoulou, Maria, Kastritis, Efstathios, Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8541338/ https://www.ncbi.nlm.nih.gov/pubmed/34696256 http://dx.doi.org/10.3390/vaccines9101148 |
Ejemplares similares
-
SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
por: Zagouri, Flora, et al.
Publicado: (2021) -
Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients
por: Liontos, Michalis, et al.
Publicado: (2021) -
Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
por: Zagouri, Flora, et al.
Publicado: (2022) -
SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
por: Terpos, Evangelos, et al.
Publicado: (2022) -
CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)